Suven Pharmaceuticals Limited
NSE:SUVENPHAR.NS
1249.95 (INR) • At close October 17, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Omzet
| 10,513.537 | 13,403.288 | 12,898.038 | 9,799.36 | 8,069.421 | 3,662.556 |
| Kosten van de omzet
| 6,390.263 | 5,854.225 | 5,550.859 | 4,202.035 | 3,246.065 | 1,511.854 |
| Brutowinst
| 4,123.274 | 7,549.063 | 7,347.179 | 5,597.325 | 4,823.356 | 2,150.702 |
| Brutowinstmarge
| 0.392 | 0.563 | 0.57 | 0.571 | 0.598 | 0.587 |
| Onderzoek- en ontwikkelingskosten
| 111.2 | 85.857 | 103.545 | 110.575 | 141.315 | 0 |
| Algemene en administratieve kosten
| 576.322 | 188.974 | 170.64 | 160.517 | 137.506 | 68.225 |
| Verkoop- en marketingkosten
| 34.775 | 176.359 | 198.031 | 105.25 | 126.841 | 67.151 |
| Verkoop-, algemene en administratieve kosten
| 611.097 | 1,105.109 | 368.671 | 265.767 | 264.347 | 135.376 |
| Overige kosten
| 619.051 | 463.638 | 14.708 | 10.487 | 2.589 | 390.243 |
| Bedrijfskosten
| 611.097 | 2,361.04 | 1,918.918 | 1,483.661 | 1,209.197 | 520.875 |
| Bedrijfsresultaat
| 3,512.177 | 5,188.023 | 5,416.277 | 4,098.933 | 3,583.785 | 3,905.839 |
| Bedrijfsresultaat ratio
| 0.334 | 0.387 | 0.42 | 0.418 | 0.444 | 1.066 |
| Totaal overige inkomsten en kosten netto
| 544.539 | 409.275 | 1,259.622 | 577.808 | 461.333 | -117.029 |
| Inkomen voor belasting
| 4,056.716 | 5,597.298 | 6,675.898 | 4,676.741 | 4,045.118 | 1,578.671 |
| Inkomen voor belasting ratio
| 0.386 | 0.418 | 0.518 | 0.477 | 0.501 | 0.431 |
| Belastingkosten
| 1,053.911 | 1,484.395 | 2,137.85 | 1,053.323 | 875.101 | 485.928 |
| Nettowinst
| 3,002.805 | 4,112.9 | 4,538.049 | 3,623.418 | 3,170.017 | 1,092.743 |
| Nettowinstmarge
| 0.286 | 0.307 | 0.352 | 0.37 | 0.393 | 0.298 |
| WPA (Winst Per Aandeel)
| 11.8 | 16.16 | 17.83 | 14.23 | 6.23 | 4.29 |
| Verwaterde WPA
| 11.8 | 16.16 | 17.83 | 14.23 | 6.23 | 4.29 |
| EBITDA
| 4,058.133 | 6,128.985 | 6,387.042 | 5,050.923 | 4,419.945 | 1,709.188 |
| EBITDA ratio
| 0.386 | 0.457 | 0.495 | 0.515 | 0.548 | 0.467 |